Alkermes plc (NasdaqGS: ALKS)
Salud · Biotecnología · IE
46,85 $
+3,08 % hoy · +60,1 % 1 año
Alkermes plc (NasdaqGS: ALKS) opera en la industria de biotecnología dentro del sector salud. Su valor en bolsa es de 7,87 mil M $ y tiene 2050 empleados.
En los últimos doce meses la acción ha subido un 60,1 % y ha cotizado entre 27,00 y 55,67.
Tweenvest puntúa a Alkermes plc en cuatro factores: calidad 79/100, valor 24/100, crecimiento 49/100. Su punto más fuerte es calidad.
Evolución de la cotización de ALKS
Cifras clave
- Capitalización
- 7,87 mil M $
- Ingresos (últ. 12 m)
- 1,75 mil M $
- PER
- —
- BPA
- -0,02
- Rent. por dividendo
- —
- Beta (5 años)
- 0,23
- Máximo 52 semanas
- 55,67 $
- Mínimo 52 semanas
- 27,00 $
- Volumen medio (3 m)
- —
- Acciones en circulación
- 168,04 M
- Empleados
- 2050
- Próximos resultados
- —
Sobre Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
- ISIN
- IE00B56GVS15
- Fundada en
- 1987
- Cotiza desde
- 16 jul 1991
- Bolsa
- Nasdaq Global Select
- Divisa
- USD
Otras empresas de biotecnología
| Empresa | Capitalización | Precio | Día |
|---|---|---|---|
| Summit Therapeutics Inc.NasdaqGM: SMMT | 8,40 mil M $ | 10,50 $ | -1,59 % |
| Protagonist Therapeutics, Inc.NasdaqGM: PTGX | 8,30 mil M $ | 127,16 $ | +2,00 % |
| Rhythm Pharmaceuticals, Inc.NasdaqGM: RYTM | 7,97 mil M $ | 115,02 $ | +4,70 % |
| Twist Bioscience CorporationNasdaqGS: TWST | 7,93 mil M $ | 116,35 $ | +3,82 % |
| Grifols, S.A.BME: GRF | 7,50 mil M $ | 11,06 € | -3,07 % |
| Kiniksa Pharmaceuticals International, plcNasdaqGS: KNSA | 7,47 mil M $ | 95,05 $ | -0,06 % |
| Cytokinetics, IncorporatedNasdaqGS: CYTK | 7,15 mil M $ | 51,32 $ | -0,64 % |
| Oruka Therapeutics, Inc.NasdaqCM: ABIO | 7,15 mil M $ | 30,00 $ | -28,37 % |